Teva Pharmaceutical Industries Ltd (NYSE:TEVA) was the recipient of a significant decrease in short interest during the month of March. As of March 29th, there was short interest totalling 59,397,239 shares, a decrease of 9.1% from the March 15th total of 65,322,254 shares. Based on an average daily trading volume, of 10,761,075 shares, the days-to-cover ratio is presently 5.5 days. Currently, 5.9% of the company’s stock are short sold.
Several research firms recently commented on TEVA. Cantor Fitzgerald set a $18.00 target price on Teva Pharmaceutical Industries and gave the company a “hold” rating in a report on Thursday, December 28th. ValuEngine lowered Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a report on Friday, February 2nd. Vetr lowered Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating and set a $21.73 target price on the stock. in a report on Monday, March 12th. Bank of America dropped their target price on Teva Pharmaceutical Industries from $17.00 to $16.00 and set an “underperform” rating on the stock in a report on Friday, February 9th. Finally, Mizuho raised Teva Pharmaceutical Industries from a “neutral” rating to a “buy” rating and increased their target price for the company from $19.12 to $23.00 in a report on Tuesday, January 9th. Eleven equities research analysts have rated the stock with a sell rating, fourteen have issued a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Hold” and an average price target of $19.67.
In related news, EVP Mark Sabag sold 5,050 shares of the stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $19.68, for a total value of $99,384.00. Following the transaction, the executive vice president now owns 44,517 shares of the company’s stock, valued at $876,094.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders sold 10,734 shares of company stock worth $204,795 in the last three months. 7.10% of the stock is currently owned by corporate insiders.
Several institutional investors and hedge funds have recently made changes to their positions in TEVA. Calton & Associates Inc. acquired a new stake in shares of Teva Pharmaceutical Industries during the fourth quarter worth about $108,000. Global Financial Private Capital LLC acquired a new stake in shares of Teva Pharmaceutical Industries during the fourth quarter worth about $193,000. Wetherby Asset Management Inc. acquired a new stake in shares of Teva Pharmaceutical Industries during the fourth quarter worth about $197,000. Sigma Planning Corp acquired a new stake in shares of Teva Pharmaceutical Industries during the fourth quarter worth about $214,000. Finally, Chevy Chase Trust Holdings Inc. boosted its stake in shares of Teva Pharmaceutical Industries by 81.5% during the third quarter. Chevy Chase Trust Holdings Inc. now owns 12,239 shares of the company’s stock worth $215,000 after buying an additional 5,497 shares during the period. Institutional investors and hedge funds own 58.22% of the company’s stock.
Shares of TEVA opened at $18.06 on Tuesday. Teva Pharmaceutical Industries has a fifty-two week low of $10.85 and a fifty-two week high of $33.82. The stock has a market cap of $18,354.63, a PE ratio of 4.60, a price-to-earnings-growth ratio of 1.57 and a beta of 0.67. The company has a debt-to-equity ratio of 1.91, a current ratio of 0.86 and a quick ratio of 0.58.
Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Thursday, February 8th. The company reported $0.91 earnings per share for the quarter, topping the consensus estimate of $0.77 by $0.14. Teva Pharmaceutical Industries had a negative net margin of 72.66% and a positive return on equity of 16.43%. The business had revenue of $5.46 billion during the quarter, compared to the consensus estimate of $5.29 billion. During the same quarter in the prior year, the firm earned $1.38 earnings per share. The business’s quarterly revenue was down 15.9% compared to the same quarter last year. sell-side analysts anticipate that Teva Pharmaceutical Industries will post 2.3 EPS for the current year.
TRADEMARK VIOLATION WARNING: This report was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another website, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The original version of this report can be viewed at https://www.dispatchtribunal.com/2018/04/17/teva-pharmaceutical-industries-ltd-teva-sees-significant-drop-in-short-interest.html.
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.